CNJ-294
CNJ-294 is an intermediate in the synthesis of Capmatinib (HY-13404) and a metabolite of Capmatinib (HY-13404) [1][2].
Product Specifications
CAS Number
[1029713-99-2]
UNSPSC
12352005
Target
Drug Intermediate; Drug Metabolite
Related Pathways
Metabolic Enzyme/Protease; Others
Field of Research
Others
Smiles
O=C(C1=C(F)C=C(C2=NN3C(N=C2)=NC=C3CC4=CC5=CC=CN=C5C=C4)C=C1)N
Molecular Formula
C22H15FN6O
Molecular Weight
398.39
References & Citations
[1]Qingquan Lian. Preparation method of carbamatinib. CN111825678 A. 2020-10-27.|[2]Glaenzel U, et al. Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite. Drug Metab Dispos. 2020 Oct;48 (10) :873-885.
Shipping Conditions
Room temperature
Scientific Category
Oligonucleotides
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6504824-01 0.1 mL
Uracil DNA Glycosylase, CT (UDG, UNG, Uracil DNA Glycosylase 1, UNG 1, UNG1, UNG-1, Uracil DNA Glycosylase 2, DGU, DKFZp781L1143, HIGM4, UNG15) (MaxLight 750)
Ask
View Details 
MBS6504824-02 5x 0.1 mL
Uracil DNA Glycosylase, CT (UDG, UNG, Uracil DNA Glycosylase 1, UNG 1, UNG1, UNG-1, Uracil DNA Glycosylase 2, DGU, DKFZp781L1143, HIGM4, UNG15) (MaxLight 750)
Ask
View Details 
124409-APC 100 µL
CBY1 (HRIHFB2025, ARB1, C22orf2, CBY, PGEA1, Protein Chibby Homolog 1, ARPP-binding Protein, Cytosolic Leucine-rich Protein, PIGEA-14, PKD2 Interactor, Golgi and Endoplasmic Reticulum-associated 1) (APC)
Ask
View Details